Cutthroat Cohen Looks at Demise for Being Soft SupervisorSaijel Kishan, Katherine Burton and Kelly Bit
In April 2008, three months before drug makers Elan Corp. and Wyeth were scheduled to release results of their Alzheimer’s drug trial, two health-care analysts for hedge-fund manager Steven A. Cohen warned their boss in an e-mail that a doctor, who implied he had seen inside information about the trial, said it wasn’t going well.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.
- Homicide Police Probe Deaths of Canadian Billionaire and Wife
- Stocks Gain on U.S. Tax Plan; Treasuries Decline: Markets Wrap
- Death of CSX's New CEO Renews Debate on Health Disclosures
- Bitcoin Takes Bigger Wall Street Stage With Smooth CME Debut
- Bitcoin Climbs as Futures Debut Fails to Incite Attack by Shorts